Telesat, a leading satellite operator, announced a conference call on October 29, 2026, to discuss its financial results for the third quarter and first nine months of 2026. The call will be hosted by the CEO and CFO and will include a webcast and replay options. This event is important for investors to assess Telesat's performance and outlook amid its ongoing satellite network developments.
Telesat's upcoming Q3 2026 earnings call provides a backdrop for this snapshot of the Technology sector on Pluang as of Oct 23, 2026, 22:41 WIB. Among 150 priced US tech stocks, 88 rose and 62 fell. Five9 Inc (FIVN) gained 5.37% to USD 36.98 with a typical hold time of 72 days, contrasting with Appian Corp (APPN) which rose 5.36% to USD 53.89 but has a much shorter typical hold time of 20 days and a strong buy order activity of 98%. Datadog Inc (DDOG) also advanced 4.75% to USD 270.00, showing a typical hold time of 77 days and 100% buy order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
